Shots:

• The P-III DUBLIN-3 trial evaluates plinabulin + docetaxel vs docetaxel alone in 599 patients with 2L & 3L NSCLC EGFR wild type- with measurable lung lesion
• The trial met its 1EPs & 2EPs i.e improvement in OS- ORR- PFS- and OS rate @24 & 36mos. (22.1% vs 12.5% & 11.7% vs 5.3%); @48mos. OS (10.6% vs 0%)- reduction in incidence of Grade 4 neutropenia (5.3% vs 27.8%)
• The company plans to seek US FDA and NMPA approval for plinabulin + docetaxel in NSCLC based on the clinical benefit and safety profile. Additionally- the NDA submission for NSCLC indication is expected in H1’22

Ref: Globenewswire | Image: Linkedin